The agreement between BioNTech’s subsidiary BioNTech UK and the UK government is focused on accelerating clinical trials for ...

Biopharmaceutical company BioNTech has announced funding of up to £1 billion into the United Kingdom over the next 10 years.

German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

BioNTech will invest up to £1bn in UK life sciences over 10 years, launching new AI and R&D centres in London and Cambridge.

Hundreds of highly skilled jobs will be created, and new research centres will be set up aimed at making new advances in ...

BioNTech said it plans to invest up to 1 billion pounds ($1.34 billion) over the next 10 years to expand its research and development activities for innovative medicines in the U.K.

German vaccine pioneer BioNTech (Nasdaq: BNTX) today revealed that its UK subsidiary has signed a grant agreement with the UK ...